Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Genome Med. 2019 Jul 25;11(1):46. doi: 10.1186/s13073-019-0651-9.
A multi-disciplinary approach to promote engagement, inform decision-making and support clinicians and patients is increasingly advocated to realise the potential of genome-scale sequencing in the clinic for patient benefit. Here we describe the results of establishing a genomic medicine multi-disciplinary team (GM-MDT) for case selection, processing, interpretation and return of results.
We report a consecutive case series of 132 patients (involving 10 medical specialties with 43.2% cases having a neurological disorder) undergoing exome sequencing over a 10-month period following the establishment of the GM-MDT in a UK NHS tertiary referral hospital. The costs of running the MDT are also reported.
In total 76 cases underwent exome sequencing following triage by the GM-MDT with a clinically reportable molecular diagnosis in 24 (31.6%). GM-MDT composition, operation and rationale for whether to proceed to sequencing are described, together with the health economics (cost per case for the GM-MDT was £399.61), the utility and informativeness of exome sequencing for molecular diagnosis in a range of traits, the impact of choice of sequencing strategy on molecular diagnostic rates and challenge of defining pathogenic variants. In 5 cases (6.6%), an alternative clinical diagnosis was indicated by sequencing results. Examples were also found where findings from initial genetic testing were reconsidered in the light of exome sequencing including TP63 and PRKAG2 (detection of a partial exon deletion and a mosaic missense pathogenic variant respectively); together with tissue-specific mosaicism involving a cytogenetic abnormality following a normal prenatal array comparative genomic hybridization.
This consecutive case series describes the results and experience of a multidisciplinary team format that was found to promote engagement across specialties and facilitate return of results to the responsible clinicians.
为了实现基因组测序在临床应用中的潜力,为患者带来获益,提倡采用多学科方法来促进参与、告知决策,并为临床医生和患者提供支持。本研究介绍了建立一个基因组医学多学科团队(GM-MDT)以进行病例选择、处理、解释和结果报告的结果。
我们报告了一个英国 NHS 三级转诊医院在建立 GM-MDT 后 10 个月内连续进行的 132 例患者(涉及 10 个医学专科,其中 43.2%的病例存在神经障碍)的外显子组测序的连续病例系列。还报告了运行 MDT 的成本。
GM-MDT 进行了 76 例病例的筛选,其中 24 例(31.6%)有临床可报告的分子诊断。描述了 GM-MDT 的组成、运作方式以及是否进行测序的理由,同时还描述了健康经济学(GM-MDT 每个病例的成本为 399.61 英镑)、外显子组测序在一系列特征中的分子诊断效用和信息量、测序策略选择对分子诊断率的影响以及致病性变异定义的挑战。在 5 例(6.6%)中,测序结果提示存在其他替代临床诊断。还发现了一些病例,通过外显子组测序重新考虑了初始基因检测结果,包括 TP63 和 PRKAG2(分别检测到部分外显子缺失和镶嵌错义致病性变异);以及在正常的产前微阵列比较基因组杂交后,涉及细胞遗传学异常的组织特异性镶嵌现象。
本连续病例系列描述了多学科团队模式的结果和经验,发现这种模式可以促进跨专业的参与,并为负责的临床医生提供结果报告。